Website maintenance took place on Thursday 30 April 2026. If you experience any issues, please contact us.
Sponsor content
352 result(s) found, displaying 121 to 130
-
Prescription medicine decision summaryAustralian prescription medicine decision summary
-
Prescription medicine decision summaryTGA decision: Lagevrio (molnupiravir) is approved for the treatment of adults with COVID-19.
-
Prescription medicine registrationActive ingredients: molnupiravir.
-
Prescription medicine registrationActive ingredients: molnupiravir.
-
Prescription medicine registrationActive ingredients: pneumococcal purified capsular polysaccharides.
-
Prescription medicine registrationActive ingredients: pneumococcal purified capsular polysaccharides.
-
Cancellation by sponsorRequested by Merck Sharp & Dohme (Australia) Pty Ltd
-
Cancellation by sponsorRequested by Merck Sharp & Dohme (Australia) Pty Ltd
-
Cancellation by sponsorRequested by Merck Sharp & Dohme (Australia) Pty Ltd
-
Cancellation by sponsorRequested by Merck Sharp & Dohme (Australia) Pty Ltd